D J O'Brien1, G Flannelly, E E Mooney, M Foley. 1. University College Dublin School of Medicine and Medical Science, National Maternity Hospital, Dublin, Ireland. donal.j.obrien@ucd.ie
Abstract
OBJECTIVE: To study the relationship between lymphovascular space involvement (LVSI) in stage 1a or 1b well-differentiated endometrial cancer and survival. DESIGN: Retrospective study consisting of a search of an oncology database to identify women with endometrial cancer between January 1990 and December 2004. SETTING: Tertiary referral centre, Dublin, Ireland. SAMPLE: Women who had well-differentiated stage 1a or 1b endometrial cancer. METHODS: During the period 1990-2004, 226 patients with endometrial cancer were treated in the National Maternity Hospital, Dublin. We looked at all patients who had well-differentiated endometrioid adenocarcinoma of the endometrium with invasion of <50% thickness of the myometrium. Forty-one patients fulfilled these inclusion criteria. The presence or absence of LSVI was determined by review of haematoxylin and eosin sections. Patients were followed for 5 years or till death if earlier. Mortality was calculated. Statistical analysis was performed using Fisher's exact test. An odds ratio and 95% confidence interval was calculated using fixed effect Mantel-Haenszel model. MAIN OUTCOME MEASURES: Death from recurrence of endometrial cancer. RESULTS: Of the 41 patients, five (12%) were found to have (LVSI). Of the five patients with LVSI, three (60%) patients died of recurrence. All patients with recurrence died of disease and none of the patients without LVSI died (0 of 36). Overall, the survival rate was 92.7%. The presence of LVSI was a highly significant predictor of recurrence (P < 0.001). CONCLUSION: In patients with early stage well-differentiated adenocarcinoma of the endometrium, the presence of LVSI is associated with a high risk of death.
OBJECTIVE: To study the relationship between lymphovascular space involvement (LVSI) in stage 1a or 1b well-differentiated endometrial cancer and survival. DESIGN: Retrospective study consisting of a search of an oncology database to identify women with endometrial cancer between January 1990 and December 2004. SETTING: Tertiary referral centre, Dublin, Ireland. SAMPLE: Women who had well-differentiated stage 1a or 1b endometrial cancer. METHODS: During the period 1990-2004, 226 patients with endometrial cancer were treated in the National Maternity Hospital, Dublin. We looked at all patients who had well-differentiated endometrioid adenocarcinoma of the endometrium with invasion of <50% thickness of the myometrium. Forty-one patients fulfilled these inclusion criteria. The presence or absence of LSVI was determined by review of haematoxylin and eosin sections. Patients were followed for 5 years or till death if earlier. Mortality was calculated. Statistical analysis was performed using Fisher's exact test. An odds ratio and 95% confidence interval was calculated using fixed effect Mantel-Haenszel model. MAIN OUTCOME MEASURES: Death from recurrence of endometrial cancer. RESULTS: Of the 41 patients, five (12%) were found to have (LVSI). Of the five patients with LVSI, three (60%) patients died of recurrence. All patients with recurrence died of disease and none of the patients without LVSI died (0 of 36). Overall, the survival rate was 92.7%. The presence of LVSI was a highly significant predictor of recurrence (P < 0.001). CONCLUSION: In patients with early stage well-differentiated adenocarcinoma of the endometrium, the presence of LVSI is associated with a high risk of death.
Authors: Yushen Qian; Erqi L Pollom; Chika Nwachukwu; Kira Seiger; Rie von Eyben; Ann K Folkins; Elizabeth A Kidd Journal: Gynecol Oncol Date: 2017-07-11 Impact factor: 5.482
Authors: Ricardo dos Reis; Jennifer K Burzawa; Audrey T Tsunoda; Masayoshi Hosaka; Michael Frumovitz; Shannon N Westin; Mark F Munsell; Pedro T Ramirez Journal: Int J Gynecol Cancer Date: 2015-09 Impact factor: 3.437
Authors: S Jaishankar; P M Pifer; R Bhargava; A Keller; H B Musunuru; A K Patel; P Sukumvanich; M Boisen; J L Berger; S Taylor; M Courtney-Brooks; A Olawaiye; J Lesnock; R Edwards; J A Vargo; S Beriwal Journal: Clin Oncol (R Coll Radiol) Date: 2022-03-06 Impact factor: 4.925
Authors: Jane E Girling; Jacqueline F Donoghue; Fiona L Lederman; Leonie M Cann; Marc G Achen; Steven A Stacker; Peter Aw Rogers Journal: Reprod Biol Endocrinol Date: 2010-07-08 Impact factor: 5.211
Authors: Koji Matsuo; Todd B Sheridan; Kiyoshi Yoshino; Takahito Miyake; Karina E Hew; Dwight D Im; Neil B Rosenshein; Seiji Mabuchi; Takayuki Enomoto; Tadashi Kimura; Anil K Sood; Lynda D Roman Journal: Cancer Med Date: 2012-09-14 Impact factor: 4.452
Authors: S Bendifallah; G Canlorbe; E Raimond; D Hudry; C Coutant; O Graesslin; C Touboul; F Huguet; A Cortez; E Daraï; M Ballester Journal: Br J Cancer Date: 2014-05-08 Impact factor: 7.640